Crossmark

Comprehensive safety evaluation of isatuximab in multiple myeloma using disproportionality analysis of FAERS and meta-analysis of randomized controlled trials

Crossref DOI link: https://doi.org/10.1038/s41598-024-83014-1

Published Online: 2024-12-30

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Favas Karimbanathottathil, Muhammed https://orcid.org/0000-0001-8068-6839
Yoosuf, Beema T https://orcid.org/0009-0001-3584-6212
Mamatha, M

Bansal, Dipika https://orcid.org/0000-0003-4520-3293
License Information

Text and Data Mining valid from 2024-12-30

Version of Record valid from 2024-12-30
More Information

Article History

Received: 24 September 2024

Accepted: 10 December 2024

First Online: 30 December 2024

Declarations

:

: The authors declare no competing interests.

Document is current

Any future updates will be listed below